Evgeny Arons

1.7k total citations
46 papers, 1.0k citations indexed

About

Evgeny Arons is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Evgeny Arons has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 27 papers in Immunology and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Evgeny Arons's work include Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (19 papers) and Toxin Mechanisms and Immunotoxins (12 papers). Evgeny Arons is often cited by papers focused on Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (19 papers) and Toxin Mechanisms and Immunotoxins (12 papers). Evgeny Arons collaborates with scholars based in United States, United Kingdom and France. Evgeny Arons's co-authors include Robert J. Kreitman, Maryalice Stetler‐Stevenson, Mark Raffeld, Katherine R. Calvo, Laura Roth, Liqiang Xi, Wyndham H. Wilson, Hong Zhou, Paul S. Meltzer and Sean Davis and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Evgeny Arons

44 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evgeny Arons United States 18 785 509 445 312 251 46 1.0k
Roland Schnell Germany 17 300 0.4× 662 1.3× 506 1.1× 200 0.6× 500 2.0× 30 1.2k
Laurens P. Kil Netherlands 11 456 0.6× 271 0.5× 386 0.9× 232 0.7× 164 0.7× 14 811
Virginia Snell United States 14 209 0.3× 249 0.5× 387 0.9× 542 1.7× 391 1.6× 19 1.1k
Pin Lu United States 13 456 0.6× 359 0.7× 205 0.5× 185 0.6× 158 0.6× 29 648
Thomas Wossning Germany 10 447 0.6× 314 0.6× 677 1.5× 334 1.1× 120 0.5× 14 1.1k
Marcus Dühren-von Minden Germany 10 465 0.6× 332 0.7× 410 0.9× 319 1.0× 122 0.5× 11 886
Virginia Kelly United States 16 624 0.8× 316 0.6× 232 0.5× 322 1.0× 394 1.6× 34 1.2k
Archito T. Tamayo United States 16 246 0.3× 393 0.8× 413 0.9× 631 2.0× 412 1.6× 34 1.2k
Martin F. M. de Rooij Netherlands 7 539 0.7× 400 0.8× 229 0.5× 186 0.6× 153 0.6× 9 663
Jens Stanelle Germany 11 142 0.2× 361 0.7× 274 0.6× 463 1.5× 466 1.9× 13 975

Countries citing papers authored by Evgeny Arons

Since Specialization
Citations

This map shows the geographic impact of Evgeny Arons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Arons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Arons more than expected).

Fields of papers citing papers by Evgeny Arons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgeny Arons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Arons. The network helps show where Evgeny Arons may publish in the future.

Co-authorship network of co-authors of Evgeny Arons

This figure shows the co-authorship network connecting the top 25 collaborators of Evgeny Arons. A scholar is included among the top collaborators of Evgeny Arons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgeny Arons. Evgeny Arons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schroeder, Brett, Constance M. Yuan, Hao‐Wei Wang, et al.. (2025). Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. Blood. 147(7). 725–738.
2.
Arons, Evgeny, Chin‐Hsien Tai, Yuelin Liu, et al.. (2024). Non-V600E BRAF mutations and treatment for hairy cell leukemia. Blood. 145(17). 1957–1961. 4 indexed citations
3.
Kreitman, Robert J., M N Gould, Hong Zhou, et al.. (2023). COVID-19 in patients with classic and variant hairy cell leukemia. Blood Advances. 7(23). 7161–7168. 2 indexed citations
4.
Kreitman, Robert J. & Evgeny Arons. (2021). Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Reviews. 51. 100888–100888. 6 indexed citations
5.
Arons, Evgeny, Hong Zhou, Daniel C. Edelman, et al.. (2020). Expression of the muscle-associated gene MYF6 in hairy cell leukemia. PLoS ONE. 15(2). e0227586–e0227586. 6 indexed citations
6.
Chihara, Dai, Evgeny Arons, Maryalice Stetler‐Stevenson, et al.. (2019). Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. Journal of Clinical Oncology. 37(15_suppl). 7003–7003. 3 indexed citations
7.
Chihara, Dai, Evgeny Arons, Maryalice Stetler‐Stevenson, et al.. (2019). Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood. 134(Supplement_1). 1536–1536. 3 indexed citations
8.
Arons, Evgeny, Maryalice Stetler‐Stevenson, Constance M. Yuan, et al.. (2018). Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing. Blood. 132(Supplement 1). 1861–1861. 1 indexed citations
9.
Ho, Mitchell, et al.. (2018). Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. PubMed. 2(1). 12–21. 1 indexed citations
10.
Arons, Evgeny, Hong Zhou, Daniel C. Edelman, et al.. (2015). Impact of telomere length on survival in classic and variant hairy cell leukemia. Leukemia Research. 39(12). 1360–1366. 8 indexed citations
11.
Arons, Evgeny, Sharon Adams, David Venzon, Ira Pastan, & Robert J. Kreitman. (2014). Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. British Journal of Haematology. 166(5). 729–738. 11 indexed citations
12.
Korde, Neha, Sham Mailankody, Evgeny Arons, et al.. (2014). Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders. Blood. 124(21). 5647–5647. 1 indexed citations
13.
Waterfall, Joshua J., Evgeny Arons, Robert L. Walker, et al.. (2013). High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias. Nature Genetics. 46(1). 8–10. 180 indexed citations
14.
Kreitman, Robert J., Evgeny Arons, Maryalice Stetler‐Stevenson, et al.. (2011). Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leukemia & lymphoma. 52(sup2). 82–86. 17 indexed citations
15.
Arons, Evgeny & Robert J. Kreitman. (2011). Molecular variant of hairy cell leukemia with poor prognosis. Leukemia & lymphoma. 52(sup2). 99–102. 24 indexed citations
16.
Arons, Evgeny, et al.. (2008). PRAME expression in hairy cell leukemia. Leukemia Research. 32(9). 1400–1406. 3 indexed citations
17.
Arons, Evgeny, et al.. (2007). Immunoglobulin light chain repertoire in hairy cell leukemia. Leukemia Research. 31(9). 1231–1236. 6 indexed citations
18.
Arons, Evgeny, Lynn Sorbara, Mark Raffeld, et al.. (2005). Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunology Immunotherapy. 55(9). 1100–1110. 11 indexed citations
19.
Arons, Evgeny, et al.. (2001). Organization and Functional Analysis of the Mouse Transporter Associated with Antigen Processing 2 Promoter. The Journal of Immunology. 166(6). 3942–3951. 18 indexed citations
20.
Zusman, Tal, Evgeny Arons, Christian Bonnerot, et al.. (1996). Contribution of the intracellular domain of murine FC-gamma receptor type IIB1 to its tumor-enhancing potential. International Journal of Cancer. 68(2). 219–227. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roland Schnell Breakdown of academic impact, for papers by Laurens P. Kil Breakdown of academic impact, for papers by Virginia Snell Breakdown of academic impact, for papers by Pin Lu Breakdown of academic impact, for papers by Thomas Wossning Breakdown of academic impact, for papers by Marcus Dühren-von Minden Breakdown of academic impact, for papers by Virginia Kelly Breakdown of academic impact, for papers by Archito T. Tamayo Breakdown of academic impact, for papers by Martin F. M. de Rooij Breakdown of academic impact, for papers by Jens Stanelle
Rankless by CCL
2026